About Ikaria
Ikaria is a company based in Hampton (United States) founded in 2005 was acquired by Mallinckrodt Pharmaceuticals in March 2015.. Ikaria has raised $434.92 million across 6 funding rounds from investors including Mallinckrodt Pharmaceuticals, Arch Venture Partners and 5AM Ventures. The company has 429 employees as of December 31, 2014. Ikaria operates in a competitive market with competitors including aTyr Pharma, ReCode Therapeutics, InterMune, GEn1E and Pulmatrix, among others.
- Headquarter Hampton, United States
- Employees 429 as on 31 Dec, 2014
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$434.92 M (USD)
in 6 rounds
-
Latest Funding Round
$850 M (USD), Debt – Conventional
Jul 01, 2013
-
Investors
Mallinckrodt Pharmaceuticals
& 6 more
-
Employee Count
429
as on Dec 31, 2014
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Ikaria
Ikaria has successfully raised a total of $434.92M across 6 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $850 million completed in July 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Debt – Conventional — $850.0M
-
First Round
First Round
(26 Apr 2005)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2013 | Amount | Debt – Conventional - Ikaria | Valuation |
investors |
|
| Oct, 2009 | Amount | Series C - Ikaria | Valuation |
investors |
|
| Oct, 2008 | Amount | Series C - Ikaria | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ikaria
Ikaria has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Mallinckrodt Pharmaceuticals, Arch Venture Partners and 5AM Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on life science companies
|
Founded Year | Domain | Location | |
|
Venture capital fund backed incubator focused on the healthcare startups
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on tech sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ikaria
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Ikaria
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ikaria Comparisons
Competitors of Ikaria
Ikaria operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as aTyr Pharma, ReCode Therapeutics, InterMune, GEn1E and Pulmatrix, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Protein biologics are developed for treating rare diseases.
|
|
| domain | founded_year | HQ Location |
Precision medicines for lung-related diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapies in pulmonology and orphan fibrotic diseases.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of inflammatory and rare diseases
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of respiratory diseases
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics are developed for various diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ikaria
Frequently Asked Questions about Ikaria
When was Ikaria founded?
Ikaria was founded in 2005.
Where is Ikaria located?
Ikaria is headquartered in Hampton, United States. It is registered at Hampton, Virginia, United States.
Is Ikaria a funded company?
Ikaria is a funded company, having raised a total of $434.92M across 6 funding rounds to date. The company's 1st funding round was a Series C of $154.6K, raised on Apr 26, 2005.
How many employees does Ikaria have?
As of Dec 31, 2014, the latest employee count at Ikaria is 429.
What does Ikaria do?
Ikaria was founded in 2005 and is headquartered in Hampton, United States. Focus is placed on developing therapies for respiratory-related cardiopulmonary disorders within the biotechnology sector. INOtherapy is provided, incorporating INOMAX (nitric oxide) for inhalation, which has received FDA approval for hypoxic respiratory failure. Late-stage trials are ongoing for bronchopulmonary dysplasia and acute respiratory distress syndrome. Pipeline efforts address hepatorenal syndrome, heart failure, tissue ischemia, and vascular leakage.
Who are the top competitors of Ikaria?
Ikaria's top competitors include aTyr Pharma, ReCode Therapeutics and Pulmatrix.
Who are Ikaria's investors?
Ikaria has 7 investors. Key investors include Mallinckrodt Pharmaceuticals, Arch Venture Partners, 5AM Ventures, Venrock, and Washington Research Foundation.